TOP STORIES

• BUSINESS Regeneron to Hire 73 Rhinology Sales Reps to Back Dupixent Label Expansion
  August 28, 2024

• REGULATORY High-Dose Mecobalamin Now in Line to Become Japan’s 1st ALS Med in 9-Plus Years
  August 28, 2024

• ACADEMIA A Time for Patience - 5: Focus Turning to Early and Preclinical ALS Treatment, TDP-43 as New Target
  August 28, 2024

• BUSINESS A Time for Patience - 4: Toho University Joins Ionis’ Global Trial for FUS-ALS
  August 27, 2024

• REGULATORY MHLW to Address Drug Loss, Generic Industry Reform in FY2025 Budget Request
  August 26, 2024

• BUSINESS Bayer Japan Says No Job Cuts to Soothe Employees’ Nerves as Xarelto Generics Loom
  August 23, 2024

• BUSINESS A Time for Patience - 1: New Drugs for ALS Emerging, Some Close to Approval; Can They Meet Unmet Needs?
  August 22, 2024

• COMMENTARY Japan’s Drug-Loss Landscape Is Transforming Driven by Private Sector
  August 21, 2024

• BUSINESS Bayer Set to Finally List Xarelto AG in December, Espha as Distributor
  August 20, 2024

• REGULATORY Japan Approves Equa, Onglyza Generics towards December Listing, 1st DPP-4 Copycat on Horizon?
  August 19, 2024

• ACADEMIA As Kisunla Approval Nears, Japanese Alzheimer’s KOL Hails Increase in Options
  August 9, 2024

• REGULATORY Chuikyo Disappointed over Industry Survey on 2024 Drug Pricing Reform
  August 8, 2024

• REGULATORY Novartis’ Fabhalta, UCB’s Briviact and More to Join NHI Price List on Aug. 15
  August 8, 2024

• REGULATORY Dupixent Braces for Third Re-Pricing, LEO/Lilly Meds Face Spillover Cuts
  August 8, 2024

• REGULATORY AstraZeneca’s Tezspire to Face 4.1% CEA Price Cut in November
  August 8, 2024

• BUSINESS NCC Offshoot’s 1st CAR-T Therapy Set to Enter Clinic Next Year: CEO
  August 7, 2024

• COMMENTARY Analysis: All Eyes Riveted on FY2024 Drug Price Survey for Off-Year Revision
  August 6, 2024

• BUSINESS Japan Major Pharmas Endure Market Crash, but Biotechs Take a Hit
  August 6, 2024

• BUSINESS Eisai Stands Firmly Behind Leqembi Profile despite EU Rejection
  August 5, 2024

• REGULATORY Lilly’s Alzheimer’s Med Donanemab Now in Line for Japan Approval
  August 2, 2024

ページ

• « 先頭
• ‹ Prev
• …
• 25
• 26
• 27
• 28
• 29
• 30
• 31
• 32
• 33
• …
• Next ›
• 最終 »